Latest & greatest articles for pneumonia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pneumonia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pneumonia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pneumonia

61. In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids

In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids | BMJ Evidence-Based Medicine We use cookies to improve our service (...) name or password? You are here In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids Article Text Commentary General medicine In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids

Evidence-Based Medicine (Requires free registration)2017

62. Cohort study: Oral antibiotics are as effective as intravenous antibiotics for postdischarge treatment of complicated pneumonia in children

Cohort study: Oral antibiotics are as effective as intravenous antibiotics for postdischarge treatment of complicated pneumonia in children Oral antibiotics are as effective as intravenous antibiotics for postdischarge treatment of complicated pneumonia in children | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oral antibiotics are as effective as intravenous antibiotics for postdischarge treatment of complicated pneumonia in children Article Text Therapeutics/Prevention Cohort study Oral antibiotics are as effective as intravenous antibiotics

Evidence-Based Medicine (Requires free registration)2017

63. Cohort study: General practices that reduce antibiotic prescribing for self-limiting respiratory tract infections by 10% can expect to see one extra patient with pneumonia each year and one peritonsillar abscess each decade

Cohort study: General practices that reduce antibiotic prescribing for self-limiting respiratory tract infections by 10% can expect to see one extra patient with pneumonia each year and one peritonsillar abscess each decade General practices that reduce antibiotic prescribing for self-limiting respiratory tract infections by 10% can expect to see one extra patient with pneumonia each year and one peritonsillar abscess each decade | Evidence-Based Medicine This site uses cookies. By continuing (...) respiratory tract infections by 10% can expect to see one extra patient with pneumonia each year and one peritonsillar abscess each decade Article Text Therapeutics/Prevention Cohort study General practices that reduce antibiotic prescribing for self-limiting respiratory tract infections by 10% can expect to see one extra patient with pneumonia each year and one peritonsillar abscess each decade Oliver van Hecke , Chris C Butler Statistics from Altmetric.com Commentary on: Gulliford MC , Moore MV , Little

Evidence-Based Medicine (Requires free registration)2017

77. Antibiotics for pediatric outpatients with community-acquired pneumonia

Antibiotics for pediatric outpatients with community-acquired pneumonia

DynaMed Plus2017

78. Antibiotics for pediatric inpatients with community-acquired pneumonia

Antibiotics for pediatric inpatients with community-acquired pneumonia

DynaMed Plus2017